



December 13, 2017

ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai

Obesity Rate in UAE is Estimated to be Twice the Worldwide Rate

SAN CLEMENTE, Calif., Dec. 13, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLI), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its *ReShape*® Integrated Dual Balloon System from Al Zahrawi Medical, a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar. This order, the second since Al Zahrawi's initial stocking order in August 2017, is to support increased demand for the *Reshape* Integrated Dual Balloon System from a leading hospital customer's growing bariatric program in Dubai.

Obesity in the UAE has been estimated to be twice the worldwide rate. While close to 30% of the global population is estimated to be obese, according to a University of Washington's Institute for Health Metrics and Evaluation report from 2013, more than 66% of men and 60% of women in the UAE were estimated to be obese. Over 5,000 weight loss surgeries were performed in the UAE in 2015, an increase of more than 30% from 2014, as reported by the Emirates Obesity Association under the Emirates Medical Association.

About ReShape Lifesciences Inc.

ReShape Lifesciences is a medical device company focused on technology to treat obesity and metabolic diseases. *vBloc*® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the *vBloc* System, is designed to help patients with a Body Mass Index (BMI) of 40-45, or 35-39.9 with a minimum of one related comorbid condition, feel full, eat less and lose weight by intermittently blocking hunger signals on the vagus nerve. The FDA-approved *ReShape*® Integrated Dual Balloon System involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 BMI, and at least one co-morbidity, lose weight. The Gastric Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect, "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of ReShape Medical, Inc., including unexpected costs or liabilities; the ability to recognize the benefits of the acquisition and that the acquisition may involve unexpected costs or liabilities; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our *vBloc*® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our *vBloc* System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our *vBloc* System; physician adoption of our *vBloc* System and *vBloc* Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in Exhibit 99.3 of our current report on Form 8-K filed July 26, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-

looking statements contained in this document as a result of new information, future events or otherwise.



View original content with multimedia:<http://www.prnewswire.com/news-releases/reshape-lifesciences-announces-stocking-order-from-medical-supplier-in-dubai-300570462.html>

SOURCE ReShape Lifesciences Inc.

News Provided by Acquire Media